Indaptus Therapeutics (INDP) vs Prothena (PRTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Prothena (PRTA) over the past year, gaining 52.4% versus a loss of 21.6%. Over five years, PRTA leads with a -83.3% price change compared with -98.3% for INDP. Indaptus Therapeutics is the larger company by market cap ($433.2 million vs $422.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | PRTA |
|---|---|---|
| Share price | $2.82 | $8.22 |
| Market cap | $433.16M | $422.10M |
| 1-day change | -9.90% | -2.14% |
| YTD return | -3.09% | -13.93% |
| 1-year return | +52.43% | -21.56% |
| 5-year return | -98.26% | -83.28% |
| EPS (TTM) | $-3.16 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $9.68M |
| Revenue growth (YoY) | — | -92.83% |
| Net income (latest FY) | $-20.85M | $-244.09M |
| Operating margin | — | -2216.44% |
| Net margin | — | -2520.57% |
| 52-week high | $5.96 | $11.80 |
| 52-week low | $0.92 | $7.70 |
| Distance from 52-week high | -52.68% | -30.34% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +160.34% |
| Average volume | 712.87K | 487.91K |
| Shares outstanding | 153.60M | 51.35M |
| Employees | 5 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed PRTA by 74.0 percentage points over the past year.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Prothena
PRTA stock →Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.
Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees
INDP vs PRTA FAQ
Which is bigger, Indaptus Therapeutics or Prothena?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $433.16M compared with $422.10M for Prothena (PRTA).
Which stock has performed better over the past year, INDP or PRTA?
INDP returned +52.43% over the past 12 months, compared with -21.56% for PRTA (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Prothena in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.